Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Teberif vs Rebif in Relapsing-Remitting Multiple Sclerosis
NCT02727907Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by BIOCAD. Started Feb 2015; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02727907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727907.